CR10881A - Nueva utilizacion terapeutica para el tratamiento de las leucemias - Google Patents

Nueva utilizacion terapeutica para el tratamiento de las leucemias

Info

Publication number
CR10881A
CR10881A CR10881A CR10881A CR10881A CR 10881 A CR10881 A CR 10881A CR 10881 A CR10881 A CR 10881A CR 10881 A CR10881 A CR 10881A CR 10881 A CR10881 A CR 10881A
Authority
CR
Costa Rica
Prior art keywords
treatment
therapeutic use
leukemies
new therapeutic
leukemia
Prior art date
Application number
CR10881A
Other languages
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38268928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10881(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CR10881A publication Critical patent/CR10881A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invencion tiene como objetivo una nueva utilizacion terapeutica para el tratamiento de las leucemias, principalmente de las leucemias mieloides.
CR10881A 2006-12-28 2009-06-22 Nueva utilizacion terapeutica para el tratamiento de las leucemias CR10881A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0611492A FR2910813B1 (fr) 2006-12-28 2006-12-28 Nouvelle utilisation therapeutique pour le traitement des leucemies

Publications (1)

Publication Number Publication Date
CR10881A true CR10881A (es) 2009-08-12

Family

ID=38268928

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10881A CR10881A (es) 2006-12-28 2009-06-22 Nueva utilizacion terapeutica para el tratamiento de las leucemias

Country Status (40)

Country Link
US (1) US8236811B2 (es)
EP (1) EP2107906B1 (es)
JP (1) JP5317987B2 (es)
KR (1) KR101458233B1 (es)
CN (1) CN101568338B (es)
AR (1) AR064550A1 (es)
AT (1) ATE534392T1 (es)
AU (1) AU2007347370B2 (es)
BR (1) BRPI0720963A2 (es)
CA (1) CA2672716C (es)
CL (1) CL2007003846A1 (es)
CO (1) CO6190610A2 (es)
CR (1) CR10881A (es)
CY (1) CY1112443T1 (es)
DK (1) DK2107906T3 (es)
EA (1) EA016873B1 (es)
EC (1) ECSP099449A (es)
ES (1) ES2377843T3 (es)
FR (1) FR2910813B1 (es)
GT (1) GT200900168A (es)
HK (1) HK1138189A1 (es)
HR (1) HRP20120170T1 (es)
JO (1) JO2748B1 (es)
MA (1) MA31100B1 (es)
MX (1) MX2009007054A (es)
MY (1) MY148515A (es)
NI (1) NI200900129A (es)
NO (1) NO20092496L (es)
NZ (1) NZ577991A (es)
PE (1) PE20081548A1 (es)
PL (1) PL2107906T3 (es)
PT (1) PT2107906E (es)
RS (1) RS52162B (es)
SI (1) SI2107906T1 (es)
SV (1) SV2009003315A (es)
TN (1) TN2009000234A1 (es)
TW (1) TWI433678B (es)
UA (1) UA97505C2 (es)
WO (1) WO2008102075A2 (es)
ZA (1) ZA200904478B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
EP2638911A1 (en) 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
AU2014362999B2 (en) * 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
US20230136218A1 (en) * 2019-09-23 2023-05-04 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
MD1861G2 (ro) 1994-11-14 2002-09-30 Уорнер-Ламберт Кампэни Derivaţi ai 6-arilpirido[2,3-d]pirimidinelor şi naftiridinelor, compoziţie farmaceutică pe baza lor, metode de tratament şi de inhibare a proliferării şi migraţiei celulei receptorului tirozinkinazei
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EP1218336A2 (en) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
PE20011066A1 (es) * 2000-01-25 2001-10-22 Warner Lambert Co PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
AP2002002643A0 (en) 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
JP2004519422A (ja) 2000-08-04 2004-07-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) * 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Also Published As

Publication number Publication date
EA200970639A1 (ru) 2010-04-30
CL2007003846A1 (es) 2009-01-23
KR20090103899A (ko) 2009-10-01
NO20092496L (no) 2009-07-23
TWI433678B (zh) 2014-04-11
HK1138189A1 (en) 2010-08-20
WO2008102075A2 (fr) 2008-08-28
CO6190610A2 (es) 2010-08-19
MX2009007054A (es) 2009-08-12
WO2008102075A3 (fr) 2008-12-11
TW200833343A (en) 2008-08-16
UA97505C2 (ru) 2012-02-27
PE20081548A1 (es) 2009-01-04
JP5317987B2 (ja) 2013-10-16
US20090298790A1 (en) 2009-12-03
NI200900129A (es) 2011-12-13
RS52162B (en) 2012-08-31
CA2672716A1 (fr) 2008-08-28
CN101568338A (zh) 2009-10-28
TN2009000234A1 (fr) 2010-10-18
KR101458233B1 (ko) 2014-11-04
EA016873B1 (ru) 2012-08-30
NZ577991A (en) 2012-01-12
ATE534392T1 (de) 2011-12-15
ECSP099449A (es) 2009-07-31
HRP20120170T1 (hr) 2012-03-31
CN101568338B (zh) 2011-11-23
MY148515A (en) 2013-04-30
AU2007347370A1 (en) 2008-08-28
PL2107906T3 (pl) 2012-04-30
JP2010514743A (ja) 2010-05-06
AR064550A1 (es) 2009-04-08
SV2009003315A (es) 2010-02-05
SI2107906T1 (sl) 2012-03-30
US8236811B2 (en) 2012-08-07
BRPI0720963A2 (pt) 2014-03-18
EP2107906A2 (fr) 2009-10-14
GT200900168A (es) 2010-03-19
CY1112443T1 (el) 2015-12-09
MA31100B1 (fr) 2010-01-04
PT2107906E (pt) 2012-03-05
ES2377843T3 (es) 2012-04-02
FR2910813B1 (fr) 2009-02-06
CA2672716C (fr) 2013-05-28
DK2107906T3 (da) 2012-03-19
AU2007347370B2 (en) 2013-05-23
EP2107906B1 (fr) 2011-11-23
JO2748B1 (en) 2014-03-15
ZA200904478B (en) 2010-08-25
FR2910813A1 (fr) 2008-07-04

Similar Documents

Publication Publication Date Title
CR11292A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
ECSP099502A (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
DE502007002639D1 (de) Plasmabrennerkopf, plasmabrennerschaft und plasmabrenner
CU20080044A7 (es) Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
EA201171367A1 (ru) Винилиндазолильные соединения
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
HN2007015177A (es) Derivados de triazolopirazina
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
ECSP077360A (es) Compuestos sulfonamida
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
PA8784301A1 (es) Oxazolidinonas sustituidas y su uso
ATE458487T1 (de) Tumorbehandlung mit gliotoxin-derivaten
EA200970465A1 (ru) Укороченные пептиды pth циклической конформации
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
BRPI0807804A2 (pt) " arilciclopentenos substituídos como agentes terapêuticos ".
HN2005030779A (es) Nonadepsipeptidos acilados ii
CR10881A (es) Nueva utilizacion terapeutica para el tratamiento de las leucemias
BRPI1012344A2 (pt) uso de g-csf para a extensão da janela de tempo terapêutica para terapia de derrame trombolítico.

Legal Events

Date Code Title Description
FC Refusal